Literature DB >> 12084445

Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration.

Kayo Hosaka1, Kazunari Ishii, Setsu Sakamoto, Tetsuya Mori, Masahiro Sasaki, Nobutsugu Hirono, Etsuro Mori.   

Abstract

OBJECTIVES: Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neurodegenerative disorders that may be accompanied by dementia and parkinsonism as clinical symptoms. The purpose of this study was to elucidate cerebral metabolic differences of these two diseases with cognitive impairments by [18F] fluorodeoxyglucose (FDG) and positron emission tomography (PET).
METHODS: A total of 12 patients with PSP (age: 62.8+/-6.0 years old, m: 7, f: 5, Mini-Mental State Examination (MMSE): 23.4+/-2.6), 12 patients with CBD (age: 64.8+/-6.3 years old, m: 6, f: 6, MMSE: 22.9+/-4.5), and age-matched healthy subjects (normal control (NC)) (age: 63.8+/-7.7 years old, m: 7, f: 5) were subjected to FDG-PET to obtain glucose metabolic images. We compared regional cerebral metabolic images by a voxel-by-voxel analysis with statistical parametric mapping (SPM) among PSP, CBD, and NC subjects, and evaluated differences of hypometabolic regions.
RESULTS: The patients with PSP showed reduced cerebral glucose metabolism in the medial and lateral frontal gyri, basal ganglia, and midbrain compared with NC, whereas the patients with CBD showed significant reduction in the parietal lobes (p<0.001). SPM also revealed parietal hypometabolism in CBD patients compared with PSP patients (p<0.001).
CONCLUSIONS: The predominant parietal glucose metabolic reduction in CBD patients was different from previously reported findings. This finding would be the characteristic substance of patients with CBD accompanying cognitive impairments. Our findings suggest that measurement of glucose metabolism by PET and a voxel-based analysis is useful to understand the pathophysiology of these two diseases with cognitive impairments.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12084445     DOI: 10.1016/s0022-510x(02)00102-8

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  23 in total

1.  A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism (Niccolini and Politis, 2016) : Reply to Jean-Claude Baron Letter to Editor.

Authors:  Marios Politis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03       Impact factor: 9.236

2.  Identification by [99mTc]ECD SPECT of anterior cingulate hypoperfusion in progressive supranuclear palsy, in comparison with Parkinson's disease.

Authors:  Andrea Varrone; Marco Pagani; Elena Salvatore; Dario Salmaso; Valeria Sansone; Marianna Amboni; Flavio Nobili; Giuseppe De Michele; Alessandro Filla; Paolo Barone; Sabina Pappatà; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-24       Impact factor: 9.236

Review 3.  Gray matter atrophy in progressive supranuclear palsy: meta-analysis of voxel-based morphometry studies.

Authors:  Hai Cun Shi; Jian Guo Zhong; Ping Lei Pan; Pei Rong Xiao; Yuan Shen; Li Juan Wu; Hua Liang Li; Yuan Ying Song; Gui Xiang He; Hong Ye Li
Journal:  Neurol Sci       Date:  2013-03-30       Impact factor: 3.307

4.  Evaluation of cortical atrophy between progressive supranuclear palsy and corticobasal degeneration by hemispheric surface display of MR images.

Authors:  Masato Taki; Kazunari Ishii; Tetsuya Fukuda; Yoshio Kojima; Etsuro Mori
Journal:  AJNR Am J Neuroradiol       Date:  2004 Nov-Dec       Impact factor: 3.825

Review 5.  Apathy and the basal ganglia.

Authors:  Richard Levy; Virginie Czernecki
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

6.  Computer-assisted diagnostic system for neurodegenerative dementia using brain SPECT and 3D-SSP.

Authors:  Kazunari Ishii; Tomonori Kanda; Takafumi Uemura; Naokazu Miyamoto; Toshiki Yoshikawa; Kenichi Shimada; Shingo Ohkawa; Satoshi Minoshima
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-16       Impact factor: 9.236

7.  H1 haplotype of the MAPT gene is associated with lower regional gray matter volume in healthy carriers.

Authors:  Elisa Canu; Marina Boccardi; Roberta Ghidoni; Luisa Benussi; Cristina Testa; Michela Pievani; Matteo Bonetti; Giuliano Binetti; Giovanni B Frisoni
Journal:  Eur J Hum Genet       Date:  2008-10-15       Impact factor: 4.246

8.  FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants.

Authors:  Nicholas Zalewski; Hugo Botha; Jennifer L Whitwell; Val Lowe; Dennis W Dickson; Keith A Josephs
Journal:  J Neurol       Date:  2014-02-04       Impact factor: 4.849

9.  Fully automatic diagnostic system for early- and late-onset mild Alzheimer's disease using FDG PET and 3D-SSP.

Authors:  Kazunari Ishii; Atsushi K Kono; Hiroki Sasaki; Naokazu Miyamoto; Tetsuya Fukuda; Setsu Sakamoto; Etsuro Mori
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-10       Impact factor: 9.236

Review 10.  [Differential diagnostics of Parkinson's disease with nuclear medicine procedures].

Authors:  P T Meyer; F Amtage; S Hellwig
Journal:  Nervenarzt       Date:  2014-06       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.